Laura Sepp-Lorenzino, PhD, is Scientific Advisor, Executive Vice President and former Chief Scientific Officer at Intellia Therapeutics, a leading clinical-stage genome editing company developing novel, potentially curative medicines leveraging CRISPR-based technologies. Before joining Intellia, Laura was Vice President, Head of Nucleic Acid Therapies, and a member of the External Innovation team at Vertex Pharmaceuticals Incorporated, with previous positions as Vice President and Entrepreneur-in-Residence at Alnylam Pharmaceuticals, Inc., and Executive Director RNA Therapeutics at Merck & Co., Inc.

In addition to her extensive experience in nucleic acid therapies, Laura has expertise in oncology drug discovery and development, which she acquired earlier in her career by leading the Cancer Research Department at Merck West Point and working as Assistant Attending Molecular Biologist at Memorial Sloan Kettering Cancer Center.

She received her undergraduate degree in Biochemistry and Pharmacy from the University of Buenos Aires, Argentina, and her Master of Science and PhD in Biochemistry from New York University. Laura is a member of the Board of Directors of Taysha Gene Therapies, Alliance for Regenerative Medicine, and Sail Biomedicines. She also sits on the Scientific Advisory Boards of Thermo Fisher Scientific; UK Medical Research Council, Nucleic Acid Therapy Accelerator; and Arsenal Capital Partners. Laura is a member of the Editorial Boards of Nucleic Acid Therapeutics and Molecular Therapy Nucleic Acids.